Jazz Pharmaceuticals plc financial data

Symbol
JAZZ on Nasdaq
Industry
Pharmaceutical Preparations
Location
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin, Ireland
State of incorporation
Ireland
Fiscal year end
December 31
Former names
JAZZ PHARMACEUTICALS INC (to 1/18/2012)
Latest financial report
10-K - Q4 2024 - Feb 26, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 313 % +24.6%
Quick Ratio 41.3 % -19.4%
Return On Assets 4.77 % +29.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.7M shares -3.66%
Common Stock, Shares, Outstanding 60.6M shares -2.61%
Entity Public Float 6.41B USD -16.3%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 61.8M shares -2.3%
Weighted Average Number of Shares Outstanding, Diluted 66M shares -8.41%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 4.07B USD +6.12%
Costs and Expenses 3.35B USD +2.97%
Operating Income (Loss) 717M USD +23.9%
Income Tax Expense (Benefit) -91.4M USD +23.8%
Net Income (Loss) Attributable to Parent 560M USD +35%
Earnings Per Share, Basic 9.06 USD/shares +38.3%
Earnings Per Share, Diluted 8.65 USD/shares +41.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.41B USD +60.2%
Accounts Receivable, after Allowance for Credit Loss, Current 717M USD +1.55%
Inventory, Net 480M USD -19.5%
Other Assets, Current 262M USD -18.5%
Assets, Current 4.63B USD +34.7%
Deferred Income Tax Assets, Net 560M USD +17.2%
Operating Lease, Right-of-Use Asset 53.6M USD -18%
Intangible Assets, Net (Excluding Goodwill) 4.76B USD -12.2%
Goodwill 1.72B USD -2.1%
Other Assets, Noncurrent 114M USD +69.7%
Assets 12B USD +5.43%
Accounts Payable, Current 77.9M USD -24.2%
Accrued Liabilities, Current 911M USD +14.7%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 1.04B USD -32.4%
Deferred Income Tax Liabilities, Net 677M USD -20.2%
Operating Lease, Liability, Noncurrent 38.9M USD -34.3%
Other Liabilities, Noncurrent 86.6M USD -17.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -948M USD -12.5%
Retained Earnings (Accumulated Deficit) 1.13B USD +28.3%
Stockholders' Equity Attributable to Parent 4.09B USD +9.55%
Liabilities and Equity 12B USD +5.43%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 267M USD -16.7%
Net Cash Provided by (Used in) Financing Activities -56.6M USD -89.8%
Net Cash Provided by (Used in) Investing Activities -272M USD -5539%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 60.6M shares -2.61%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -62.9M USD -122%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.41B USD +60.2%
Deferred Tax Assets, Valuation Allowance 509M USD +63%
Deferred Tax Assets, Gross 1.58B USD +19.1%
Operating Lease, Liability 53.3M USD -31.9%
Depreciation 7.65M USD +1.04%
Payments to Acquire Property, Plant, and Equipment 6.9M USD +80.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 455M USD -34.9%
Lessee, Operating Lease, Liability, to be Paid 62.9M USD -30.5%
Operating Lease, Liability, Current 14.3M USD -24.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.6M USD -25.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 16.6M USD -27.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +18.5%
Deferred Income Tax Expense (Benefit) -66.4M USD -0.49%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.62M USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Three 10.3M USD -27.3%
Deferred Tax Assets, Operating Loss Carryforwards 307M USD +3.68%
Unrecognized Tax Benefits 126M USD +2.68%
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.02M USD -28.8%
Amortization of Intangible Assets 627M USD +3.13%
Deferred Tax Assets, Net of Valuation Allowance 1.07B USD +5.57%
Share-based Payment Arrangement, Expense 248M USD +9.35%